Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations

touchIN CONVERSATION for touchONCOLOGY Listen to Dr Yasushi Goto (National Cancer Center Hospital, Tokyo, Japan) in conversation with Professor Paul Paik (Memorial Sloan Kettering Cancer Center, New York, USA) on how to optimize the management of patients with NSCLC and MET alterations.  In Part 1 they respond to questions from the oncology and respiratory clinical communities on: Biomarker testing in advanced NSCLC Identifying patients with METex14 skipping mutations Targeting METex14 skipping mutations In Part 2, they respond to questions from the oncology and respiratory clinical communities on: Emerging mechanisms of resistance to EGFR-TKI therapy  Targeting MET amplification Optimizing outcomes for patients with MET alterations This touchPODCAST is for HCPs only.  This activity is funded by an independent medical education grant from the healthcare Business of Merck KGaA, Darmstadt, Germany, and is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/met-alterations-nsclc-management/